Target ALS

Meet Dr. Fanny Elahi, MD, PhD, a dedicated neurologist-neuroscientist at the Icahn School of Medicine at Mount Sinai, and learn why she joined the Target ALS IRC (Independent Review Committee). At Target ALS, fairness and transparency are at the core of our review process. The Independent Review Committee (IRC), composed of leading experts from academia and industry, makes all funding decisions independently. This ensures that every research application is evaluated fairly, free from any organizational bias or conflicts of interest. No IRC member can apply for or receive Target ALS funding for their own work, and there are no preset limits on the number of grants awarded each cycle, allowing the best research to receive support. Dr. Elahi’s commitment and expertise highlight the collaborative efforts at Target ALS to accelerate research and bring innovative treatments to patients. Her work exemplifies the dedication and interdisciplinary approach necessary to tackle ALS. #ALSResearch #TargetALS #ScientificInnovation #Neuroscience #ResearchCollaboration #EndALS #FairFunding #TransparentReview

🎉 Announcing the 2024 Basic Biology Consortia Grant Recipients 🧬 We are thrilled to announce the recipients of this cycle’s Target ALS Basic Biology Consortia Grant Program, focusing on sporadic ALS. These grants are awarded to innovative research projects that aim to accelerate the discovery of effective treatments for ALS. At Target ALS, we aim to drive innovative research and accelerate the discovery of effective treatments for all forms of amyotrophic lateral sclerosis (ALS) so that Everyone Lives. For this funding cycle, we had 106 scientists from 76 institutions in 13 countries apply. After a rigorous review process, six outstanding projects have been awarded funding. Swipe through to learn more about these groundbreaking projects and the brilliant minds behind them. Each of these projects represents a significant step forward in our mission to end ALS. 🔗 Read full project summaries and more at https://bit.ly/3VUuN3j #ALSResearch #TargetALS #ScientificInnovation #Neuroscience #GrantAnnouncement #ResearchFunding #EndALS

What is an iPS Cell? 🔬 Eran Hornstein, M.D., Ph.D., Professor of Molecular Neuroscience at the Weizmann Institute of Science, explains the significance of iPS cells in the advancement of regenerative medicine and disease reasearch. Watch the video to learn more. #ALSResearch #ALSFacts #EveryoneLives #ALS

Happy Independence Day! #IndependenceDay #July4th

Nico van Nuland is a young scientist at Blas Cabrera Institute of Physical Chemistry in Madrid working with Dr. Javier Oroz, a Target ALS New Academic Investigator. Nico's personal connection to ALS motivates him to contribute to research to discover treatments for the disease. He encourages his peers in the young scientific community to find their motivation and passion to advance ALS research and support the community. Nicolás Van Nuland es un científico del Instituto de Química Física Blas Cabrera en Madrid que trabaja con el Dr. Javier Oroz, un "New Academic Investigator" de Target ALS. La conexión personal de Nico con la ELA lo motiva a contribuir a la investigación para descubrir tratamientos para la enfermedad. Nico le dice a sus pares de la joven comunidad científica a encontrar su motivación y pasión para avanzar en la investigación de la ELA y apoyar a la comunidad.

Despite the challenges ALS brings his way, our Founder, Dan Doctoroff, remains deeply committed to realizing our vision of a world where Everyone Lives. We are honored to have such a resilient and driven leader at the helm of Target ALS, motivating us to be bolder and work harder to accelerate ALS research, because every moment counts for the people that we serve: those living with ALS and their families. Thank you, Dan, for inspiring our team, the global scientific community, and everyone who has rallied behind us to achieve our mission. With your leadership, the world we envision is within reach.

Nico van Nuland, a scientist at Blas Cabrera Institute of Physical Chemistry in Madrid, has a personal connection to ALS; his father unfortunately passed away from the disease. Nico's father was a scientist and expert in nuclear magnetic resonance, a technique Nico himself began using in his work with Dr. Javier Oroz, a Target ALS New Academic Investigator. Nico is carrying on his father's legacy both with the technology and its application to further ALS research, which he says is his motivation in life. Watch the video to hear Nico's story. #GlobalReach #ALSResearch #ALS #EveryoneLives Nicolás Van Nuland, un científico del Instituto de Química Física Blas Cabrera en Madrid, tiene una conexión personal con la ELA; su padre falleció a causa de la enfermedad. Su padre era científico y experto en resonancia magnética nuclear, una técnica que Nico comenzó a utilizar en su trabajo con el Dr. Javier Oroz, un "New Academic Investigator" de Target ALS. Nico continúa el legado de su padre tanto con la tecnología como con su aplicación para avanzar un tratamiento para ELA, lo que, según él, es su motivación en la vida. Mire el vídeo para escuchar la historia de Nico.

What is the difference between familial als and sporadic als? 💡 Sporadic ALS is the most common form of the disease, accounting for around 90% all cases. It is diagnosed in patients who do not have a family history of ALS. Familial, or inherited, ALS runs in families and accounts for the remaining 10% of cases. It can be caused by one of several genetic mutations that are passed from parents to their children. Read more ALS FAQs: https://bit.ly/4cCyaT6 #ALS #ALSFacts #ALSFAQ

At Target ALS, we are dedicated to leveraging innovative talent and technology to investigate neurodegenerative disorders such as Frontotemporal Dementia (FTD), which shares genetic causes and disease biology with ALS. One critical overlap is the aggregation of TDP-43, a protein vital for RNA molecule function in cells. Target ALS-funded research has pioneered a novel technique using RNA aptamers—protein-binding RNA molecules that facilitate high-resolution detection and visualization of very small molecules. This groundbreaking method enables the detection of TDP-43 aggregates in human tissue well before ALS or FTD symptoms appear. The team is now working to adapt this technology for biofluid samples from individuals living with ALS, paving the way for early diagnosis and treatment. This remarkable progress is the result of a collaborative effort involving leading researchers: Dr.Jenna Gregory, Senior Clinical Lecturer & Consultant Pathologist, University of Aberdeen, Dr.Neil Shneider from Columbia University, Dr.Mathew H. Horrocks from The University of Edinburgh, and Drs.Gian Gaetano Tartaglia and Elsa Zacco from the Istituto Italiano di Tecnologia . Join us in celebrating this groundbreaking progress and its potential to transform ALS and FTD diagnosis and care. #ALSResearch #ALS #FTD #NeurodegenerativeDiseases #EveryoneLives

A key stage for emerging scientists is their ability to transition from a postdoctoral fellowship to establishing themselves in an independent faculty appointment leading their own lab. Watch Juliet Goldsmith, Postdoctoral Researcher at the University of Pennsylvania, describe her experience as a Target ALS Springboard Fellow 👇 #ALSResearch #Innovation #Collaboration #ALS #EveryoneLives